{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:02:39Z","timestamp":1779840159655,"version":"3.53.1"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"abstract":"Zusammenfassung<\/jats:title>\n Die Anwendung von zahlreichen Neuropsychopharmaka ist mit einem relevanten\n Risiko f\u00fcr kardiovaskul\u00e4re unerw\u00fcnschte Arzneimittelwirkungen (kvUAW)\n assoziiert.<\/jats:p>\n Systematische Darstellung und Diskussion substanzspezifischer Risiken f\u00fcr\n unterschiedliche kvUAW.<\/jats:p>\n Auswertung der regulatorischen Daten aus Fachinformationen (FI) der im Jahr\n 2023 in Deutschland am h\u00e4ufigsten verordneten Neuropsychopharmaka im\n Hinblick auf das Risiko f\u00fcr kvUAW.<\/jats:p>\n Es wurden insgesamt 92 FI und innerhalb der Indikationsgruppen n=27\n Antidepressiva, n=22 Antipsychotika, n=4 Mood Stabilizer, n=12 Hypnotika,\n n=9 Sedativa und Anxiolytika, n=6 Medikamente zur Behandlung von\n Abh\u00e4ngigkeitserkrankungen, n=5 Psychostimulanzien und n=7 Antidementiva\n untersucht. Das Risiko f\u00fcr kvUAW ist am geringsten ausgepr\u00e4gt bei den Mood\n Stabilizern, Hypnotika sowie Sedativa und Anxiolytika und gering bei den\n Medikamenten zur Behandlung von Abh\u00e4ngigkeitserkrankungen, Stimulanzien und\n Antidementiva, w\u00e4hrend Antidepressiva und Antipsychotika mit dem gr\u00f6\u00dften\n Risiko assoziiert sind.<\/jats:p>\n Die hier gefundenen Ergebnisse basierend auf regulatorischen Daten\n korrespondieren weitestgehend mit der klinischen Erfahrung und der\n verf\u00fcgbaren Studienlage. Bei der Anwendung von Neuropsychopharmaka,\n insbesondere Antidepressiva und Antipsychotika, sollten kvUAW systematisch\n ber\u00fccksichtigt und klinisch regelm\u00e4\u00dfig kontrolliert werden.<\/jats:p>","DOI":"10.1055\/a-2866-8844","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T23:08:04Z","timestamp":1779404884000},"source":"Crossref","is-referenced-by-count":0,"title":["Kardiovaskul\u00e4re unerw\u00fcnschte Arzneimittelwirkungen von\n Psychopharmaka: Eine Auswertung von Daten aus Fachinformationen"],"prefix":"10.1055","author":[{"given":"Maximilian","family":"Gahr","sequence":"additional","affiliation":[{"name":"Krankenhaus f\u00fcr Psychiatrie Psychotherapie und\n Psychosomatische Medizin Schloss Werneck, Germany","place":["Werneck"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mischke","sequence":"additional","affiliation":[{"name":"Leopoldina Krankenhaus Schweinfurt, Germany","place":["Schweinfurt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-5160","authenticated-orcid":false,"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[{"name":"Alexianer Krankenhaus Aachen, Germany","place":["Aachen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"Krankenhaus f\u00fcr Psychiatrie Psychotherapie und\n Psychosomatische Medizin Schloss Werneck, Germany","place":["Werneck"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref1","first-page":"2024","article-title":"Use of Antidepressant and Anxiolytic Drugs in Scandinavian Countries between\n 2006 and 2021: A Prescription Database Study","author":"I Bojanic","year":"2024","journal-title":"Depress Anxiety"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/pds.5158","article-title":"Antidepressant use in Australia and Sweden-A cross-country comparison","volume":"30","author":"E Eek","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1177\/00048674211067720","article-title":"Trends in prescription of psychotropic medications to children and adolescents\n in Australian primary care from 2011 to 2018","volume":"56","author":"J Klau","year":"2022","journal-title":"Aust N Z J Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S2215-0366(21)00292-3","article-title":"Psychotropic medicine consumption in 65 countries and regions, 2008-19: a\n longitudinal study","volume":"8","author":"R Brauer","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.52778\/ppt20250013","article-title":"Verordnungen von Neuropsychopharmaka","volume":"32","author":"J Fritze","year":"2025","journal-title":"Psychopharmakotherapie"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-70594-0","volume-title":"Arzneiverordnungs-Report 2024","author":"W Ludwig","year":"2025"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S2215-0366(23)00262-6","article-title":"Antidepressant and antipsychotic side-effects and personalised prescribing: a\n systematic review and digital tool development","volume":"10","author":"T Pillinger","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic\n review and meta-analysis","volume":"4","author":"C Hjorthoj","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1017\/S1092852925100461","article-title":"Do antipsychotics work in people with schizophrenia? A review of outcomes and\n effect sizes","volume":"30","author":"C U Correll","year":"2025","journal-title":"CNS Spectrums"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20\u2010year follow\u2010up study of physical morbidity and mortality in relationship to\n antipsychotic treatment in a nationwide cohort of 62,250 patients with\n schizophrenia (FIN20)","volume":"19","author":"H Taipale","year":"2020","journal-title":"World psychiatry"},{"key":"ref13","first-page":"19","article-title":"Temporal trends in associations between severe mental illness and risk of\n cardiovascular disease: A systematic review and meta-analysis","author":"A M Lambert","year":"2022","journal-title":"PLoS Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0773","article-title":"Adverse Cardiovascular Effects of Psychotropic Medications","volume":"86","author":"V Androshchuk","year":"2025","journal-title":"Br J Hosp Med (Lond)"},{"key":"ref15","first-page":"243","article-title":"Cardiologic side effects of psychotropic drugs","volume":"8","author":"G Marano","year":"2011","journal-title":"J Geriatr Cardiol"},{"key":"ref17","first-page":"152","article-title":"Different number of contraindications between summaries of product\n characteristics (SmPC) of drugs with the same active ingredients \u2013 an analysis\n of data from SmPCs of neuropsychiatric drugs","volume":"88","author":"M Gahr","year":"2020","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00228-021-03209-7","article-title":"Harmonization of summaries of product characteristics (SmPCs) of drugs with the\n same active ingredients: an evaluation of SmPCs of the most frequently\n prescribed active substances","volume":"78","author":"M Gahr","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(25)01293-0","article-title":"The effects of antidepressants on cardiometabolic and other physiological\n parameters: a systematic review and network meta-analysis","volume":"406","author":"T Pillinger","year":"2025","journal-title":"Lancet"},{"key":"ref20","first-page":"687","article-title":"QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes","volume":"108","author":"K Wenzel-Seifert","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-022-06293-4","article-title":"Antipsychotics and risk of QT prolongation: a pharmacovigilance study","volume":"240","author":"C Bordet","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hup.915","article-title":"Cardiac side effects of psychiatric drugs","volume":"23","author":"P Mackin","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic\n nervous system","volume":"135","author":"J Y Leung","year":"2012","journal-title":"Pharmacol Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbrc.2023.09.043","article-title":"Impact of antipsychotics and antidepressants drugs on long QT syndrome induction\n related to hERG channel dysfunction: A systematic review","volume":"681","author":"M Nemati","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.bjp.0706143","article-title":"Protein trafficking abnormalities: a new mechanism in drug-induced long QT\n syndrome","volume":"145","author":"L L Eckhardt","year":"2005","journal-title":"Br J Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0269881113515064","article-title":"Evidence for a crucial modulating role of the sodium channel in the QTc\n prolongation related to antipsychotics","volume":"28","author":"J S Silvestre","year":"2014","journal-title":"J Psychopharmacol"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2866-8844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:11:41Z","timestamp":1779837101000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2866-8844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1055\/a-2866-8844","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}